$DYAI Flag PRs
$1.72
Dyadic International, Inc. Announces Closing of Sale of Industrial Technology
Business to Dupont Industrial Biosciences
GlobeNewswire(Thu 10:16AM EST)
Dyadic International, Inc. Earnings Analysis: Q3, 2015 By the Numbers
at Capital Cube(Wed, Dec 16)
Shares Outstanding: 31.01M
Float: 18.66M
% Held by Insiders: 6.75%
% Held by Institutions: 0.60%
Shares Short : N/A
Headlines
Dyadic International, Inc., a biotechnology company, discovers, develops, manufactures, and sells enzymes and other proteins for the bioenergy, biochemical, biopharmaceutical, and industrial enzyme industries. It utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and manufacture of enzymes and other proteins for various markets. The company licenses its patented and proprietary technologies; and provides research and development services for third parties. In addition, it manufactures and sells liquid and dry enzyme products for use in the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles, and biofuels industries. The companys C1 Platform Technology could also be used for developing and producing other biological products, such as antibodies, vaccines, proteins, and polypeptides for the biopharmaceutical industry. Dyadic International, Inc. has operations in the United States and the Netherlands. The company was founded in 1979 and is headquartered in Jupiter, Florida.
$1.72
Dyadic International, Inc. Announces Closing of Sale of Industrial Technology
Business to Dupont Industrial Biosciences
GlobeNewswire(Thu 10:16AM EST)
Dyadic International, Inc. Earnings Analysis: Q3, 2015 By the Numbers
at Capital Cube(Wed, Dec 16)
Shares Outstanding: 31.01M
Float: 18.66M
% Held by Insiders: 6.75%
% Held by Institutions: 0.60%
Shares Short : N/A
Headlines
Dyadic International, Inc., a biotechnology company, discovers, develops, manufactures, and sells enzymes and other proteins for the bioenergy, biochemical, biopharmaceutical, and industrial enzyme industries. It utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and manufacture of enzymes and other proteins for various markets. The company licenses its patented and proprietary technologies; and provides research and development services for third parties. In addition, it manufactures and sells liquid and dry enzyme products for use in the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles, and biofuels industries. The companys C1 Platform Technology could also be used for developing and producing other biological products, such as antibodies, vaccines, proteins, and polypeptides for the biopharmaceutical industry. Dyadic International, Inc. has operations in the United States and the Netherlands. The company was founded in 1979 and is headquartered in Jupiter, Florida.
